MX2009008491A - Tratamiento de disfuncion erectil y eyaculacion prematura copatologicas. - Google Patents

Tratamiento de disfuncion erectil y eyaculacion prematura copatologicas.

Info

Publication number
MX2009008491A
MX2009008491A MX2009008491A MX2009008491A MX2009008491A MX 2009008491 A MX2009008491 A MX 2009008491A MX 2009008491 A MX2009008491 A MX 2009008491A MX 2009008491 A MX2009008491 A MX 2009008491A MX 2009008491 A MX2009008491 A MX 2009008491A
Authority
MX
Mexico
Prior art keywords
erectile dysfunction
premature ejaculation
treatment
phosphodiesterase inhibitor
comorbid premature
Prior art date
Application number
MX2009008491A
Other languages
English (en)
Inventor
James V Winkler
Kevin Bilyard
David Bar-Or
Original Assignee
Dmi Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009008491(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dmi Biosciences Inc filed Critical Dmi Biosciences Inc
Publication of MX2009008491A publication Critical patent/MX2009008491A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

La presente invención proporciona un método para tratar disfunción de eyaculación y eréctil prematura, comorbida. En particular, el método comprende administrar una cantidad efectiva de un material de tramadol y una cantidad efectiva de un inhibidor de fosfodiesterasa. La presente invención también proporciona una composición farmacéutica que comprende un transportador farmacéuticamente aceptable, un material de tramadol y un inhibidor de fosfodiesterasa. La presente invención proporciona además un equipo que comprende un material de tramadol y un inhibidor de fosfodiesterasa.
MX2009008491A 2007-02-12 2008-02-12 Tratamiento de disfuncion erectil y eyaculacion prematura copatologicas. MX2009008491A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88936907P 2007-02-12 2007-02-12
PCT/US2008/053710 WO2008100926A1 (en) 2007-02-12 2008-02-12 Treatment of comorbid premature ejaculation and erectile dysfunction

Publications (1)

Publication Number Publication Date
MX2009008491A true MX2009008491A (es) 2010-01-20

Family

ID=39690490

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008491A MX2009008491A (es) 2007-02-12 2008-02-12 Tratamiento de disfuncion erectil y eyaculacion prematura copatologicas.

Country Status (17)

Country Link
US (3) US20080262094A1 (es)
EP (2) EP2120570B1 (es)
JP (2) JP2010518167A (es)
KR (3) KR20140054312A (es)
CN (1) CN101657101B (es)
AU (1) AU2008216356C1 (es)
BR (1) BRPI0807282A2 (es)
CA (1) CA2677690C (es)
DK (1) DK2120570T3 (es)
ES (1) ES2384481T3 (es)
HK (1) HK1132882A1 (es)
MX (1) MX2009008491A (es)
NZ (1) NZ579169A (es)
PL (1) PL2120570T3 (es)
SG (1) SG174079A1 (es)
WO (1) WO2008100926A1 (es)
ZA (1) ZA200906186B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140054312A (ko) * 2007-02-12 2014-05-08 디엠아이 바이오사이언시스 인코포레이티드 조루 및 발기부전을 동시에 치료하는 방법
CA2677691C (en) * 2007-02-12 2012-07-31 David Bar-Or Reducing side effects of tramadol
CN103263435B (zh) * 2013-05-17 2014-08-13 宋博 聚维酮碘的制药用途
MX369874B (es) * 2013-11-29 2019-11-22 Laboratorios Liomont S A De C V Composicion farmaceutica para el tratamiento de la disfunción erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel.
WO2015134695A1 (en) * 2014-03-07 2015-09-11 Vyrix Pharmaceuticals, Inc. Method of mitigating the side effects of a phosphodiesterase type v inhibitor in a subject
US20180071269A1 (en) 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
KR101778688B1 (ko) 2016-05-31 2017-09-15 한양대학교 에리카산학협력단 포스포다이에스터라제―5 억제제를 포함하는 약제학적 복합제제

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US533669A (en) 1895-02-05 And conveying appaeatus
US3830934A (en) 1967-07-27 1974-08-20 Gruenenthal Chemie Analgesic and antitussive compositions and methods
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
ATE173603T1 (de) 1990-04-25 1998-12-15 Vivus Inc Behandlung von erektionversagen
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5151448A (en) * 1991-07-12 1992-09-29 Crenshaw Roger T Method for treating premature ejaculation
JP3381190B2 (ja) * 1991-09-06 2003-02-24 マクニーラブ・インコーポレーテツド トラマドール物質およびアセトアミノフェンを含んでなる組成物並びにそれの使用
US5223541A (en) 1991-09-13 1993-06-29 Mcneilab, Inc. Tramadol n-oxide material, enantiomers and compositions thereof, and their use
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US20010006967A1 (en) * 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US5861431A (en) 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
DE19601745C1 (de) * 1996-01-19 1997-10-09 Gruenenthal Gmbh Verfahren zur Racematspaltung von Tramadol
DE19601744C2 (de) 1996-01-19 1998-04-16 Gruenenthal Gmbh Verfahren zur Herstellung der Enantiomeren von O-Demethyltramadol
IL119121A (en) 1996-08-22 2000-11-21 Chemagis Ltd Process for the purification of (RR-SS)-2-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexanol hydrochloride
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
PL335619A1 (en) * 1997-03-11 2000-05-08 Darwin Discovery Ltd Dosage forms including separate parts containing r and s enantiomers
DE69830728T2 (de) * 1997-04-11 2006-05-18 Nippon Shinyaku Co., Ltd. Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
US6037360A (en) 1997-10-28 2000-03-14 Vivus, Incorporated Administration of 5-HT3 receptor antagonists to treat premature ejaculation
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
JP2003525845A (ja) * 1997-10-28 2003-09-02 ヴィヴァス・インコーポレイテッド 勃起機能不全の処置のためのホスホジエステラーゼインヒビターの局所投与
DE59803108D1 (de) * 1997-11-12 2002-03-21 Bayer Ag 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
PT1685839E (pt) * 1997-12-22 2013-07-08 Euro Celtique Sa Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
KR100417490B1 (ko) * 1997-12-22 2004-02-05 유로-셀티크 소시에떼 아노뉨 오피오이드 제형의 남용을 방지하는 방법
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6339826B2 (en) * 1998-05-05 2002-01-15 International Business Machines Corp. Client-server system for maintaining a user desktop consistent with server application user access permissions
US6156342A (en) * 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
US6403605B1 (en) * 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US6943166B1 (en) * 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US6765010B2 (en) * 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
US20030055070A1 (en) * 1999-07-01 2003-03-20 Wilma Harrison Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
US6821975B1 (en) * 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
EP1313460A2 (en) * 1999-11-09 2003-05-28 Darwin Discovery Limited Therapeutic use and formulation of (-)-tramadol
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
CN1289071C (zh) * 2001-03-16 2006-12-13 Dmi生物科学公司 曲马朵物质在制备用于延缓男性射精的药物中的用途
WO2002092059A1 (en) * 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
JP4504013B2 (ja) * 2001-08-06 2010-07-14 ユーロ−セルティーク エス．エイ． 放出可能な及び封鎖されたアンタゴニストを有するオピオイドアゴニスト製剤
US7019010B2 (en) * 2001-09-27 2006-03-28 Novertis Ag Combinations
WO2003042216A1 (en) 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
WO2004069167A2 (en) * 2003-01-31 2004-08-19 Nastech Pharmaceutical Company Inc. Method and compositions for treating male infertility
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20050054688A1 (en) * 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
US20060149480A1 (en) * 2004-02-26 2006-07-06 Lundeen James E Method of making combination medicament and medicament made thereby
US7483535B2 (en) * 2004-09-15 2009-01-27 Hewlett-Packard Development Company, L.P. Transmission of generalized scalable bit-streams
US8604082B2 (en) * 2005-12-13 2013-12-10 Trinity Laboratories, Inc. Method to treat premature ejaculation in humans
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
CA2677691C (en) * 2007-02-12 2012-07-31 David Bar-Or Reducing side effects of tramadol
KR20140054312A (ko) * 2007-02-12 2014-05-08 디엠아이 바이오사이언시스 인코포레이티드 조루 및 발기부전을 동시에 치료하는 방법
US20100120780A1 (en) * 2007-04-19 2010-05-13 Chandra Ulagaraj Singh Treatments for premature ejaculation in humans

Also Published As

Publication number Publication date
JP2010518167A (ja) 2010-05-27
EP2120570A1 (en) 2009-11-25
EP2120570B1 (en) 2012-05-16
US20120018345A1 (en) 2012-01-26
WO2008100926A1 (en) 2008-08-21
US20120022071A1 (en) 2012-01-26
US20080262094A1 (en) 2008-10-23
PL2120570T3 (pl) 2012-10-31
AU2008216356A1 (en) 2008-08-21
KR20150089085A (ko) 2015-08-04
DK2120570T3 (da) 2012-06-25
CN101657101B (zh) 2013-12-11
BRPI0807282A2 (pt) 2014-04-29
ZA200906186B (en) 2013-02-27
JP2014077008A (ja) 2014-05-01
CA2677690C (en) 2012-05-15
EP2120570A4 (en) 2010-03-31
SG174079A1 (en) 2011-09-29
KR20140054312A (ko) 2014-05-08
AU2008216356B2 (en) 2014-04-03
EP2486927A1 (en) 2012-08-15
HK1132882A1 (en) 2010-03-12
AU2008216356C1 (en) 2014-07-24
NZ579169A (en) 2012-05-25
CA2677690A1 (en) 2008-08-21
CN101657101A (zh) 2010-02-24
ES2384481T3 (es) 2012-07-05
KR20090121315A (ko) 2009-11-25

Similar Documents

Publication Publication Date Title
MX2009008491A (es) Tratamiento de disfuncion erectil y eyaculacion prematura copatologicas.
HK1109638A1 (en) Dr5 antibodies and uses thereof dr5
UA97536C2 (en) Proteasome inhibitors
SG164368A1 (en) Treatment of cancer
MY160041A (en) Compositions and methods for treating parasitic infections
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
EP1876893A4 (en) TREATMENT OF CANCER BY THE COMBINED INHIBITION OF PROTEASOME AND TELOMERASE ACTIVITIES
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
TW200612919A (en) Lonidamine analogues and their use in male contraception and cancer treatment
WO2008030883A3 (en) Treatment of cancer
PH12014501821B1 (en) Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction
WO2007059154A3 (en) Treatment of cancers with acquired resistance to kit inhibitors
WO2008100933A3 (en) Reducing side effects of tramadol
WO2008010991A3 (en) Methods and compositions for the treatment of cancer
EP2340258A4 (en) PROCESS FOR THE SYNTHESIS AND APPLICATIONS OF INHIBITORS OF GHRELIN-O-ACYLTRANSFERASE AS POTENTIAL THERAPEUTIC AGENTS AGAINST OBESITAS AND DIABETES
WO2006009718A3 (en) Methods for treating or preventing erectile dysfunction or urinary incontinence
MX2009013950A (es) Combinaciones antitumorales que contienen un agente inhibidor de vegf e irinotecan.
UA88655C2 (ru) S-миртазапин для лечения прилива крови
EP1677754A4 (en) METHOD AND COMPOSITIONS FOR TREATING THE EFFECTIVE DYSFUNCTION
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
WO2007117289A3 (en) Methods for treating or preventing erectile dysfunction or urinary incontinence
GEP20115184B (en) Pharmacokinetically improved compounds
NZ617989A (en) Use of pnp inhibitors such as forodesine in combination with alkylating agents for treating hematologic cancers
WO2008021341A3 (en) Modafinil-based treatment for premature ejaculation

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights